版本:
中国

BRIEF-Global Blood Therapeutics to initiate mid-stage trial for the treatment of idiopathic pulmonary fibrosis

Nov 28 Global Blood Therapeutics Inc -

* Global Blood Therapeutics announces initiation of phase 2a trial of GBT440 in idiopathic pulmonary fibrosis (IPF)

* Is now conducting two clinical trials of GBT440 as potential treatment for hypoxemia in a broad range of patients with ipf

* Primary endpoint for study will be to evaluate effect of GBT440 on oxygen saturation at rest over a 90-day period

* Study will also assess safety, tolerability and pharmacokinetic profile of GBT440 in IPF patients Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐